XML 32 R12.htm IDEA: XBRL DOCUMENT v3.20.2
FAIR VALUE MEASUREMENTS
6 Months Ended
Jun. 30, 2020
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
The following tables present information about our assets that are measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value:
(In thousands)As of June 30, 2020Quoted
Prices in
Active
Markets
(Level 1)
Significant
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Cash equivalents:
U.S. treasury securities$9,999  $—  $9,999  $—  
Money market funds425,769  425,769  —  —  
Marketable debt securities:
Commercial paper11,613  —  11,613  —  
Corporate notes62,763  —  62,763  —  
U.S. government-sponsored enterprise securities244,071  —  244,071  —  
U.S. treasury securities939,978  —  939,978  —  
Marketable equity securities86,310  45,522  40,788  —  
Restricted cash (money market funds)1,483  1,483  —  —  
Total$1,781,986  $472,774  $1,309,212  $—  

(In thousands)As of December 31, 2019Quoted
Prices in
Active
Markets
(Level 1)
Significant
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Cash equivalents:
Commercial paper$3,439  $—  $3,439  $—  
U.S. treasury securities336,693  —  336,693  —  
Money market funds119,882  119,882  —  —  
Marketable debt securities:
Certificates of deposit4,301  —  4,301  —  
Commercial paper36,474  —  36,474  —  
Corporate notes146,040  —  146,040  —  
U.S. government-sponsored enterprise securities32,488  —  32,488  —  
U.S. treasury securities755,714  —  755,714  —  
Marketable equity securities13,967  13,967  —  —  
Restricted cash (money market funds)1,482  1,482  —  —  
Total$1,450,480  $135,331  $1,315,149  $—  
During the six months ended June 30, 2020 and 2019, there were no transfers between Level 1 and Level 2 financial assets. The carrying amounts reflected in our condensed consolidated balance sheets for cash, accounts receivable, net, other current assets, accounts payable and accrued expenses approximate fair value due to their short-term maturities.
In March 2020, pursuant to the Vir Agreement, we achieved a development milestone relating to ALN-HBV02 and earned a $15.0 million cash milestone and 1,111,111 shares of Vir's common stock, which were received in the second quarter of 2020. As a result of certain securities law restrictions, our Vir common stock is subject to a 180-day holding period. As such, we have recorded the investment at fair value, with the effect of the holding period restriction estimated using an option pricing valuation model, which is considered a Level 2 input. During the second quarter of 2020, we recognized an unrealized loss of $4.7 million to adjust our investment in Vir common stock to fair value as of June 30, 2020.